Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531647 · ClinicalTrials.gov registry record · Phase 1
A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01531647 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 20 participants.
The verdict
NCT01531647, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This open-label, multiple dose, single sequence crossover study will evaluate the drug-drug interaction between danoprevir/low-dose ritonavir and raltegravir in healthy volunteers. Subjects will receive raltegravir on Days 1-4 and, after a washout period of 3 days, danoprevir and low-dose ritonavir on Days 8-21, in combination with raltegravir on Days 18-21.
Interventions
- DRUG ritonavir
- DRUG danoprevir
- DRUG raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531647
The ClinicalTrials.gov registry entry for NCT01531647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ritonavir is the first listed.
NCT01531647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531647 about?
NCT01531647 is a clinical study titled "A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers". This open-label, multiple dose, single sequence crossover study will evaluate the drug-drug interaction between danoprevir/low-dose ritonavir and raltegravir in healthy volunteers. Subjects will receive raltegravir on Days 1-4 and, after a washout period of 3 days, danoprevir and low-dose ritonavir ...
What is the current status of trial NCT01531647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01531647?
The interventions under investigation include: ritonavir (DRUG), danoprevir (DRUG), raltegravir (DRUG).
Who is sponsoring clinical trial NCT01531647?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.